EMED Centrum Usług Medycznych Ewa Śmialek

At EMED Centrum Usług Medycznych Ewa Śmialek in Rzeszow, cardiovascular research focuses on major heart and vascular conditions, including atherosclerotic cardiovascular disease, atrial fibrillation, heart failure, and hyperlipidemia. These studies are designed to test new treatment options and improve prevention of serious events such as stroke, cardiovascular death, and worsening heart disease.

• Preventing stroke and systemic embolism in atrial fibrillation
• Reducing heart failure events and cardiovascular death
• Lowering vascular risk in people with high cholesterol or established cardiovascular disease

The site’s work in this area reflects a strong interest in both treatment effectiveness and long-term protection against major cardiovascular complications.

Respiratory research is a major focus at this health care site, with trials covering asthma, chronic obstructive pulmonary disease, bronchiectasis, and idiopathic pulmonary fibrosis. The studies are aimed at improving lung function, reducing flare-ups, and evaluating new therapies for people with persistent breathing problems.

• Testing treatments for severe, eosinophilic, and steroid-dependent asthma
• Evaluating options for moderate to very severe COPD
• Studying therapies to reduce pulmonary exacerbations and improve daily breathing

Several trials also look at whether new medicines can better control symptoms and prevent disease worsening over time.

Research in immune system diseases and related inflammatory conditions includes chronic spontaneous urticaria, systemic sclerosis, and allergic disorders driven by immune responses. These trials are exploring new ways to calm overactive immune activity, relieve symptoms, and improve quality of life for people with chronic inflammatory disease.

• Assessing new therapies for hives and allergic inflammation
• Studying treatment approaches for systemic sclerosis and related tissue involvement
• Evaluating immune-targeted options for long-term symptom control

This area highlights the site’s interest in therapies that address both visible symptoms and the underlying immune process.

Trials in otorhinolaryngologic diseases mainly address allergic rhinitis and rhinoconjunctivitis, especially cases linked to birch pollen or perennial allergy. The research is focused on improving symptom relief and testing whether new allergy treatments can provide better control during seasonal and ongoing exposure.

• Evaluating therapies for seasonal allergic rhinitis
• Studying treatments for rhinoconjunctivitis caused by pollen exposure
• Testing approaches to reduce nasal and eye allergy symptoms

These studies support more precise care for patients living with recurring allergy symptoms.

In the field of skin and connective tissue diseases, the site is involved in research on systemic sclerosis, a condition that can affect the skin and internal organs. The trials are intended to evaluate whether new therapies can reduce skin thickening and improve safety and tolerability for patients with this complex disease.

• Testing treatments for skin involvement in systemic sclerosis
• Assessing safety and tolerability in connective tissue disease care
• Exploring options to improve disease control and patient comfort

This work adds an important autoimmune and connective tissue dimension to the site’s broader clinical trial portfolio.

Research on immune system phenomena at the site includes studies of allergic and inflammatory responses that drive conditions such as asthma, urticaria, and allergic rhinitis. These trials aim to better understand and manage immune-related symptoms, while also evaluating whether targeted therapies can reduce exacerbations and improve overall disease control.

• Examining immune-driven inflammation in respiratory and allergy disorders
• Testing therapies that may reduce flare-ups and symptom burden
• Supporting improved diagnosis and treatment of chronic allergic disease

Overall, this research reflects a consistent focus on immune regulation across several chronic conditions.